Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Dare Bioscience assumed with a Buy at Brookline » 11:53
01/19/22
01/19
11:53
01/19/22
11:53
DARE

Dare Bioscience

$1.59 /

-0.045 (-2.76%)

Brookline analyst…

Brookline analyst Kamaraguru Raja assumed coverage of Dare Bioscience with a Buy rating and $6 price target. DARE-BV1, now called Xaciato, was approved by the FDA in December and the treatment is a "potentially best-in-class" hydrogel for bacterial vaginosis, said Raja. In addition to Xaciato's launch expected in 2022, the Ovaprene intravaginal ring hormone-free contraceptive study is expected to initiate in 2022 and sildenafil cream Phase 2b trial topline results are expected this year, noted Raja.

ShowHide Related Items >><<
DARE Dare Bioscience
$1.59 /

-0.045 (-2.76%)

DARE Dare Bioscience
$1.59 /

-0.045 (-2.76%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
DARE Dare Bioscience
$1.59 /

-0.045 (-2.76%)

DARE Dare Bioscience
$1.59 /

-0.045 (-2.76%)

Over a week ago
Conference/Events
H.C. Wainwright to hold a virtual conference » 04:55
01/13/22
01/13
04:55
01/13/22
04:55
AADI

Aadi Bioscience

$24.00 /

+0.085 (+0.36%)

, ANVS

Annovis Bio

$16.41 /

-1.105 (-6.31%)

, BBLG

Bone Biologics

$3.70 /

-0.66 (-15.14%)

, CDXS

Codexis

$25.37 /

-0.78 (-2.98%)

, COCP

Cocrystal Pharma

/

+

, DARE

Dare Bioscience

$1.69 /

-0.075 (-4.25%)

, EMMA

Emmaus Life Sciences

$2.78 /

+ (+0.00%)

, GRTS

Gritstone

$6.56 /

-0.4 (-5.75%)

, IMAC

IMAC

$1.30 /

+0.045 (+3.59%)

, KPRX

Kiora Pharmaceuticals

/

+

, LUMO

Lumos Pharma

$7.42 /

+0.32 (+4.51%)

, OCUL

Ocular Therapeutix

$6.33 /

-0.23 (-3.51%)

, PHIO

Phio Pharmaceuticals

/

+

, RGLS

Regulus

/

+

, SKYE

Skye Bioscience

/

+

, TARA

Protara Therapeutics

$6.38 /

+0.04 (+0.63%)

, TRVN

Trevena

/

+

, VRNA

Verona Pharma

$6.67 /

-0.08 (-1.19%)

, ONCR

Oncorus

$4.49 /

+0.085 (+1.93%)

, HEPA

Hepion Pharmaceuticals

$1.20 /

-0.02 (-1.65%)

, EQ

Equillium

$3.60 /

+0.04 (+1.12%)

, CLBS

Caladrius

/

+

, CABA

Cabaletta Bio

$3.47 /

-0.12 (-3.34%)

, EKSO

Ekso Bionics

$2.57 /

-0.025 (-0.97%)

, IMAB

I-Mab

$40.61 /

+1.695 (+4.36%)

, KDNY

Chinook Therapeutics

$14.25 /

+0.11 (+0.78%)

, MRNS

Marinus Pharmaceuticals

$10.85 /

-0.23 (-2.08%)

Bioconnect Virtual…

Bioconnect Virtual Conference to be held on January 10-13.

ShowHide Related Items >><<
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.38 /

+0.04 (+0.63%)

SKYE Skye Bioscience
/

+

RGLS Regulus
/

+

PHIO Phio Pharmaceuticals
/

+

ONCR Oncorus
$4.49 /

+0.085 (+1.93%)

OCUL Ocular Therapeutix
$6.33 /

-0.23 (-3.51%)

MRNS Marinus Pharmaceuticals
$10.85 /

-0.23 (-2.08%)

LUMO Lumos Pharma
$7.42 /

+0.32 (+4.51%)

KPRX Kiora Pharmaceuticals
/

+

KDNY Chinook Therapeutics
$14.25 /

+0.11 (+0.78%)

IMAC IMAC
$1.30 /

+0.045 (+3.59%)

IMAB I-Mab
$40.61 /

+1.695 (+4.36%)

HEPA Hepion Pharmaceuticals
$1.20 /

-0.02 (-1.65%)

GRTS Gritstone
$6.56 /

-0.4 (-5.75%)

EQ Equillium
$3.60 /

+0.04 (+1.12%)

EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

EKSO Ekso Bionics
$2.57 /

-0.025 (-0.97%)

DARE Dare Bioscience
$1.69 /

-0.075 (-4.25%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$25.37 /

-0.78 (-2.98%)

CABA Cabaletta Bio
$3.47 /

-0.12 (-3.34%)

BBLG Bone Biologics
$3.70 /

-0.66 (-15.14%)

ANVS Annovis Bio
$16.41 /

-1.105 (-6.31%)

AADI Aadi Bioscience
$24.00 /

+0.085 (+0.36%)

AADI Aadi Bioscience
$24.00 /

+0.085 (+0.36%)

01/11/22 Jefferies
Aadi Bioscience initiated with a Buy at Jefferies
11/24/21 H.C. Wainwright
Aadi Bioscience price target raised to $49 from $47 at H.C. Wainwright
11/23/21 Piper Sandler
Aadi Bioscience price target raised to $50 from $45 at Piper Sandler
11/10/21 Piper Sandler
Piper Sandler bullish on Aadi ahead of expected FDA decision for ABI-009
ANVS Annovis Bio
$16.41 /

-1.105 (-6.31%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
BBLG Bone Biologics
$3.70 /

-0.66 (-15.14%)

CDXS Codexis
$25.37 /

-0.78 (-2.98%)

12/31/21 Benchmark
Pfizer COVID-19 pill approval in UK could be boost for Codexis, says Benchmark
12/22/21 Craig-Hallum
Craig-Hallum bullish on Codexis, sees potential for upside to 2022 estimates
11/18/21 Benchmark
Pfizer's antiviral pill deal raises Benchmark's confidence in Codexis estimates
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
COCP Cocrystal Pharma
/

+

06/15/21 H.C. Wainwright
Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
DARE Dare Bioscience
$1.69 /

-0.075 (-4.25%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

GRTS Gritstone
$6.56 /

-0.4 (-5.75%)

10/14/21 BTIG
Gritstone assumed with a Buy at BTIG
01/21/21 BTIG
Gritstone Oncology price target raised to $35 from $17 at BTIG
01/20/21 H.C. Wainwright
Gritstone Oncology price target raised to $24 from $16 at H.C. Wainwright
01/20/21 Baird
Gritstone Oncology downgraded to Underperform from Outperform at Baird
IMAC IMAC
$1.30 /

+0.045 (+3.59%)

08/19/21 Alliance Global Partners
IMAC downgraded to Neutral at Alliance Global Partners following Q2 results
08/19/21 Alliance Global Partners
IMAC downgraded to Neutral from Buy at Alliance Global Partners
04/09/21 Alliance Global Partners
IMAC price target lowered to $2.35 from $3.10 at Alliance Global Partners
KPRX Kiora Pharmaceuticals
/

+

LUMO Lumos Pharma
$7.42 /

+0.32 (+4.51%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
OCUL Ocular Therapeutix
$6.33 /

-0.23 (-3.51%)

12/06/21 Piper Sandler
Ocular data warrant advancing acute dry eye program, says Piper Sandler
11/09/21 JMP Securities
Ocular Therapeutix price target raised to $30 from $27 at JMP Securities
10/25/21 H.C. Wainwright
Ocular Therapeutix price target lowered to $14 from $18 at H.C. Wainwright
10/24/21 Piper Sandler
Ocular Therapeutix price target lowered to $20 from $27 at Piper Sandler
PHIO Phio Pharmaceuticals
/

+

06/14/21 H.C. Wainwright
Phio Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
RGLS Regulus
/

+

09/02/21 Cantor Fitzgerald
Regulus initiated with an Overweight at Cantor Fitzgerald
05/14/21 H.C. Wainwright
Regulus price target raised to $2 from $1.50 at H.C. Wainwright
SKYE Skye Bioscience
/

+

TARA Protara Therapeutics
$6.38 /

+0.04 (+0.63%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
TRVN Trevena
/

+

03/15/21 Oppenheimer
Trevena initiated with a Perform at Oppenheimer
VRNA Verona Pharma
$6.67 /

-0.08 (-1.19%)

09/13/21
Fly Intel: Top five analyst initiations
09/13/21 H.C. Wainwright
Verona Pharma initiated with a Buy at H.C. Wainwright
ONCR Oncorus
$4.49 /

+0.085 (+1.93%)

11/12/21 Piper Sandler
Piper would be 'aggressive buyers' of Oncorus after '177 data 'as good as hoped'
06/22/21 Piper Sandler
Oncorus investor day 'incrementally positive,' says Piper Sandler
04/19/21 Piper Sandler
Oncorus selloff has nothing to do with fundamentals, says Piper Sandler
03/16/21
Fly Intel: Top five analyst initiations
HEPA Hepion Pharmaceuticals
$1.20 /

-0.02 (-1.65%)

EQ Equillium
$3.60 /

+0.04 (+1.12%)

01/12/22 Stifel
Equillium 'could be upside biased' into lupus nephritis data, says Stifel
10/29/21 Stifel
Equillium resumed with a Buy at Stifel
09/15/21
Fly Intel: Top five analyst initiations
09/15/21 Cantor Fitzgerald
Equillium initiated with an Overweight at Cantor Fitzgerald
CLBS Caladrius
/

+

11/05/21 H.C. Wainwright
Caladrius price target lowered to $8 from $10 at H.C. Wainwright
03/03/21 Brookline
Caladrius price target raised to $10 from $7 at Brookline
01/19/21 H.C. Wainwright
Caladrius price target lowered to $14 from $18.50 at H.C. Wainwright
CABA Cabaletta Bio
$3.47 /

-0.12 (-3.34%)

12/08/21 Wells Fargo
Cabaletta Bio initiated with an Overweight at Wells Fargo
10/19/21 Morgan Stanley
Cabaletta Bio assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Cabaletta Bio initiated with a Buy at Mizuho
03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
EKSO Ekso Bionics
$2.57 /

-0.025 (-0.97%)

IMAB I-Mab
$40.61 /

+1.695 (+4.36%)

09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
07/26/21 Cantor Fitzgerald
I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
07/13/21 Cantor Fitzgerald
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
KDNY Chinook Therapeutics
$14.25 /

+0.11 (+0.78%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
MRNS Marinus Pharmaceuticals
$10.85 /

-0.23 (-2.08%)

08/18/21 Truist
Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
03/10/21 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.38 /

+0.04 (+0.63%)

RGLS Regulus
/

+

ONCR Oncorus
$4.49 /

+0.085 (+1.93%)

OCUL Ocular Therapeutix
$6.33 /

-0.23 (-3.51%)

MRNS Marinus Pharmaceuticals
$10.85 /

-0.23 (-2.08%)

LUMO Lumos Pharma
$7.42 /

+0.32 (+4.51%)

KPRX Kiora Pharmaceuticals
/

+

KDNY Chinook Therapeutics
$14.25 /

+0.11 (+0.78%)

IMAC IMAC
$1.30 /

+0.045 (+3.59%)

GRTS Gritstone
$6.56 /

-0.4 (-5.75%)

EQ Equillium
$3.60 /

+0.04 (+1.12%)

EKSO Ekso Bionics
$2.57 /

-0.025 (-0.97%)

DARE Dare Bioscience
$1.69 /

-0.075 (-4.25%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$25.37 /

-0.78 (-2.98%)

CABA Cabaletta Bio
$3.47 /

-0.12 (-3.34%)

AADI Aadi Bioscience
$24.00 /

+0.085 (+0.36%)

  • 10
    Nov
  • 16
    Feb
  • 12
    Feb
  • 09
    Feb
  • 09
    Feb
TARA Protara Therapeutics
$6.38 /

+0.04 (+0.63%)

RGLS Regulus
/

+

OCUL Ocular Therapeutix
$6.33 /

-0.23 (-3.51%)

LUMO Lumos Pharma
$7.42 /

+0.32 (+4.51%)

GRTS Gritstone
$6.56 /

-0.4 (-5.75%)

DARE Dare Bioscience
$1.69 /

-0.075 (-4.25%)

CDXS Codexis
$25.37 /

-0.78 (-2.98%)

CABA Cabaletta Bio
$3.47 /

-0.12 (-3.34%)

ANVS Annovis Bio
$16.41 /

-1.105 (-6.31%)

GRTS Gritstone
$6.56 /

-0.4 (-5.75%)

AADI Aadi Bioscience
$24.00 /

+0.085 (+0.36%)

Conference/Events
H.C. Wainwright to hold a virtual conference » 04:55
01/12/22
01/12
04:55
01/12/22
04:55
AADI

Aadi Bioscience

$23.92 /

+2.265 (+10.46%)

, ANVS

Annovis Bio

$17.50 /

+1.06 (+6.45%)

, BBLG

Bone Biologics

$4.36 /

-0.91 (-17.27%)

, CDXS

Codexis

$26.15 /

+0.8 (+3.16%)

, COCP

Cocrystal Pharma

/

+

, DARE

Dare Bioscience

$1.77 /

+0.03 (+1.73%)

, EMMA

Emmaus Life Sciences

$2.78 /

+ (+0.00%)

, GRTS

Gritstone

$6.96 /

+0.08 (+1.16%)

, IMAC

IMAC

$1.26 /

+0.005 (+0.40%)

, KPRX

Kiora Pharmaceuticals

/

+

, LUMO

Lumos Pharma

$6.99 /

+0.055 (+0.79%)

, OCUL

Ocular Therapeutix

$6.57 /

+0.09 (+1.39%)

, PHIO

Phio Pharmaceuticals

$1.03 /

+0.0849 (+9.03%)

, RGLS

Regulus

/

+

, SKYE

Skye Bioscience

/

+

, TARA

Protara Therapeutics

$6.40 /

+0.14 (+2.24%)

, TRVN

Trevena

/

+

, VRNA

Verona Pharma

$6.80 /

-0.035 (-0.51%)

, ONCR

Oncorus

$4.41 /

-0.305 (-6.48%)

, HEPA

Hepion Pharmaceuticals

$1.22 /

-0.01 (-0.82%)

, EQ

Equillium

$3.56 /

+0.1 (+2.89%)

, CLBS

Caladrius

/

+

, CABA

Cabaletta Bio

$3.59 /

+0.075 (+2.13%)

, EKSO

Ekso Bionics

$2.59 /

+0.045 (+1.77%)

, IMAB

I-Mab

$38.96 /

-0.63 (-1.59%)

, KDNY

Chinook Therapeutics

$14.30 /

+0.26 (+1.85%)

, MRNS

Marinus Pharmaceuticals

$11.07 /

-0.27 (-2.38%)

Bioconnect Virtual…

Bioconnect Virtual Conference to be held on January 10-13.

ShowHide Related Items >><<
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.40 /

+0.14 (+2.24%)

SKYE Skye Bioscience
/

+

RGLS Regulus
/

+

PHIO Phio Pharmaceuticals
$1.03 /

+0.0849 (+9.03%)

ONCR Oncorus
$4.41 /

-0.305 (-6.48%)

OCUL Ocular Therapeutix
$6.57 /

+0.09 (+1.39%)

MRNS Marinus Pharmaceuticals
$11.07 /

-0.27 (-2.38%)

LUMO Lumos Pharma
$6.99 /

+0.055 (+0.79%)

KPRX Kiora Pharmaceuticals
/

+

KDNY Chinook Therapeutics
$14.30 /

+0.26 (+1.85%)

IMAC IMAC
$1.26 /

+0.005 (+0.40%)

IMAB I-Mab
$38.96 /

-0.63 (-1.59%)

HEPA Hepion Pharmaceuticals
$1.22 /

-0.01 (-0.82%)

GRTS Gritstone
$6.96 /

+0.08 (+1.16%)

EQ Equillium
$3.56 /

+0.1 (+2.89%)

EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

EKSO Ekso Bionics
$2.59 /

+0.045 (+1.77%)

DARE Dare Bioscience
$1.77 /

+0.03 (+1.73%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$26.15 /

+0.8 (+3.16%)

CABA Cabaletta Bio
$3.59 /

+0.075 (+2.13%)

BBLG Bone Biologics
$4.36 /

-0.91 (-17.27%)

ANVS Annovis Bio
$17.50 /

+1.06 (+6.45%)

AADI Aadi Bioscience
$23.92 /

+2.265 (+10.46%)

AADI Aadi Bioscience
$23.92 /

+2.265 (+10.46%)

01/11/22 Jefferies
Aadi Bioscience initiated with a Buy at Jefferies
11/24/21 H.C. Wainwright
Aadi Bioscience price target raised to $49 from $47 at H.C. Wainwright
11/23/21 Piper Sandler
Aadi Bioscience price target raised to $50 from $45 at Piper Sandler
11/10/21 Piper Sandler
Piper Sandler bullish on Aadi ahead of expected FDA decision for ABI-009
ANVS Annovis Bio
$17.50 /

+1.06 (+6.45%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
BBLG Bone Biologics
$4.36 /

-0.91 (-17.27%)

CDXS Codexis
$26.15 /

+0.8 (+3.16%)

12/31/21 Benchmark
Pfizer COVID-19 pill approval in UK could be boost for Codexis, says Benchmark
12/22/21 Craig-Hallum
Craig-Hallum bullish on Codexis, sees potential for upside to 2022 estimates
11/18/21 Benchmark
Pfizer's antiviral pill deal raises Benchmark's confidence in Codexis estimates
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
COCP Cocrystal Pharma
/

+

06/15/21 H.C. Wainwright
Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
DARE Dare Bioscience
$1.77 /

+0.03 (+1.73%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

GRTS Gritstone
$6.96 /

+0.08 (+1.16%)

10/14/21 BTIG
Gritstone assumed with a Buy at BTIG
01/21/21 BTIG
Gritstone Oncology price target raised to $35 from $17 at BTIG
01/20/21 H.C. Wainwright
Gritstone Oncology price target raised to $24 from $16 at H.C. Wainwright
01/20/21 Baird
Gritstone Oncology downgraded to Underperform from Outperform at Baird
IMAC IMAC
$1.26 /

+0.005 (+0.40%)

08/19/21 Alliance Global Partners
IMAC downgraded to Neutral at Alliance Global Partners following Q2 results
08/19/21 Alliance Global Partners
IMAC downgraded to Neutral from Buy at Alliance Global Partners
04/09/21 Alliance Global Partners
IMAC price target lowered to $2.35 from $3.10 at Alliance Global Partners
KPRX Kiora Pharmaceuticals
/

+

LUMO Lumos Pharma
$6.99 /

+0.055 (+0.79%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
OCUL Ocular Therapeutix
$6.57 /

+0.09 (+1.39%)

12/06/21 Piper Sandler
Ocular data warrant advancing acute dry eye program, says Piper Sandler
11/09/21 JMP Securities
Ocular Therapeutix price target raised to $30 from $27 at JMP Securities
10/25/21 H.C. Wainwright
Ocular Therapeutix price target lowered to $14 from $18 at H.C. Wainwright
10/24/21 Piper Sandler
Ocular Therapeutix price target lowered to $20 from $27 at Piper Sandler
PHIO Phio Pharmaceuticals
$1.03 /

+0.0849 (+9.03%)

06/14/21 H.C. Wainwright
Phio Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
RGLS Regulus
/

+

09/02/21 Cantor Fitzgerald
Regulus initiated with an Overweight at Cantor Fitzgerald
05/14/21 H.C. Wainwright
Regulus price target raised to $2 from $1.50 at H.C. Wainwright
SKYE Skye Bioscience
/

+

TARA Protara Therapeutics
$6.40 /

+0.14 (+2.24%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
TRVN Trevena
/

+

03/15/21 Oppenheimer
Trevena initiated with a Perform at Oppenheimer
VRNA Verona Pharma
$6.80 /

-0.035 (-0.51%)

09/13/21
Fly Intel: Top five analyst initiations
09/13/21 H.C. Wainwright
Verona Pharma initiated with a Buy at H.C. Wainwright
ONCR Oncorus
$4.41 /

-0.305 (-6.48%)

11/12/21 Piper Sandler
Piper would be 'aggressive buyers' of Oncorus after '177 data 'as good as hoped'
06/22/21 Piper Sandler
Oncorus investor day 'incrementally positive,' says Piper Sandler
04/19/21 Piper Sandler
Oncorus selloff has nothing to do with fundamentals, says Piper Sandler
03/16/21
Fly Intel: Top five analyst initiations
HEPA Hepion Pharmaceuticals
$1.22 /

-0.01 (-0.82%)

EQ Equillium
$3.56 /

+0.1 (+2.89%)

10/29/21 Stifel
Equillium resumed with a Buy at Stifel
09/15/21
Fly Intel: Top five analyst initiations
09/15/21 Cantor Fitzgerald
Equillium initiated with an Overweight at Cantor Fitzgerald
03/03/21
Fly Intel: Top five analyst initiations
CLBS Caladrius
/

+

11/05/21 H.C. Wainwright
Caladrius price target lowered to $8 from $10 at H.C. Wainwright
03/03/21 Brookline
Caladrius price target raised to $10 from $7 at Brookline
01/19/21 H.C. Wainwright
Caladrius price target lowered to $14 from $18.50 at H.C. Wainwright
CABA Cabaletta Bio
$3.59 /

+0.075 (+2.13%)

12/08/21 Wells Fargo
Cabaletta Bio initiated with an Overweight at Wells Fargo
10/19/21 Morgan Stanley
Cabaletta Bio assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Cabaletta Bio initiated with a Buy at Mizuho
03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
EKSO Ekso Bionics
$2.59 /

+0.045 (+1.77%)

IMAB I-Mab
$38.96 /

-0.63 (-1.59%)

09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
07/26/21 Cantor Fitzgerald
I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
07/13/21 Cantor Fitzgerald
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
KDNY Chinook Therapeutics
$14.30 /

+0.26 (+1.85%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
MRNS Marinus Pharmaceuticals
$11.07 /

-0.27 (-2.38%)

08/18/21 Truist
Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
03/10/21 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.40 /

+0.14 (+2.24%)

RGLS Regulus
/

+

ONCR Oncorus
$4.41 /

-0.305 (-6.48%)

OCUL Ocular Therapeutix
$6.57 /

+0.09 (+1.39%)

MRNS Marinus Pharmaceuticals
$11.07 /

-0.27 (-2.38%)

LUMO Lumos Pharma
$6.99 /

+0.055 (+0.79%)

KPRX Kiora Pharmaceuticals
/

+

KDNY Chinook Therapeutics
$14.30 /

+0.26 (+1.85%)

IMAC IMAC
$1.26 /

+0.005 (+0.40%)

GRTS Gritstone
$6.96 /

+0.08 (+1.16%)

EQ Equillium
$3.56 /

+0.1 (+2.89%)

EKSO Ekso Bionics
$2.59 /

+0.045 (+1.77%)

DARE Dare Bioscience
$1.77 /

+0.03 (+1.73%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$26.15 /

+0.8 (+3.16%)

CABA Cabaletta Bio
$3.59 /

+0.075 (+2.13%)

AADI Aadi Bioscience
$23.92 /

+2.265 (+10.46%)

  • 10
    Nov
  • 16
    Feb
  • 12
    Feb
  • 09
    Feb
  • 09
    Feb
  • 13
    Jan
TARA Protara Therapeutics
$6.40 /

+0.14 (+2.24%)

RGLS Regulus
/

+

OCUL Ocular Therapeutix
$6.57 /

+0.09 (+1.39%)

LUMO Lumos Pharma
$6.99 /

+0.055 (+0.79%)

GRTS Gritstone
$6.96 /

+0.08 (+1.16%)

EQ Equillium
$3.56 /

+0.1 (+2.89%)

DARE Dare Bioscience
$1.77 /

+0.03 (+1.73%)

CDXS Codexis
$26.15 /

+0.8 (+3.16%)

CABA Cabaletta Bio
$3.59 /

+0.075 (+2.13%)

ANVS Annovis Bio
$17.50 /

+1.06 (+6.45%)

GRTS Gritstone
$6.96 /

+0.08 (+1.16%)

AADI Aadi Bioscience
$23.92 /

+2.265 (+10.46%)

Conference/Events
H.C. Wainwright to hold a virtual conference » 04:55
01/11/22
01/11
04:55
01/11/22
04:55
AADI

Aadi Bioscience

$22.02 /

+0.065 (+0.30%)

, ANVS

Annovis Bio

$16.50 /

-0.445 (-2.63%)

, BBLG

Bone Biologics

$5.27 /

+1.78 (+51.00%)

, CDXS

Codexis

$25.41 /

-0.22 (-0.86%)

, COCP

Cocrystal Pharma

/

+

, DARE

Dare Bioscience

$1.74 /

-0.04 (-2.25%)

, EMMA

Emmaus Life Sciences

$2.78 /

+ (+0.00%)

, GRTS

Gritstone

$6.88 /

+0.42 (+6.50%)

, IMAC

IMAC

$1.25 /

-0.17 (-11.97%)

, KPRX

Kiora Pharmaceuticals

/

+

, LUMO

Lumos Pharma

$6.94 /

-0.135 (-1.91%)

, OCUL

Ocular Therapeutix

$6.49 /

+0.055 (+0.85%)

, PHIO

Phio Pharmaceuticals

/

+

, RGLS

Regulus

/

+

, SKYE

Skye Bioscience

/

+

, TARA

Protara Therapeutics

$6.23 /

+0.02 (+0.32%)

, TRVN

Trevena

/

+

, VRNA

Verona Pharma

$6.83 /

-0.04 (-0.58%)

, ONCR

Oncorus

$4.71 /

+0.16 (+3.52%)

, HEPA

Hepion Pharmaceuticals

$1.23 /

-0.02 (-1.60%)

, EQ

Equillium

$3.49 /

+0.02 (+0.58%)

, CLBS

Caladrius

/

+

, CABA

Cabaletta Bio

$3.52 /

+0.025 (+0.72%)

, EKSO

Ekso Bionics

$2.55 /

-0.125 (-4.68%)

, IMAB

I-Mab

$39.89 /

-0.79 (-1.94%)

, KDNY

Chinook Therapeutics

$14.04 /

-0.29 (-2.02%)

, MRNS

Marinus Pharmaceuticals

$11.35 /

+0.21 (+1.89%)

Bioconnect Virtual…

Bioconnect Virtual Conference to be held on January 10-13.

ShowHide Related Items >><<
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.23 /

+0.02 (+0.32%)

SKYE Skye Bioscience
/

+

RGLS Regulus
/

+

PHIO Phio Pharmaceuticals
/

+

ONCR Oncorus
$4.71 /

+0.16 (+3.52%)

OCUL Ocular Therapeutix
$6.49 /

+0.055 (+0.85%)

MRNS Marinus Pharmaceuticals
$11.35 /

+0.21 (+1.89%)

LUMO Lumos Pharma
$6.94 /

-0.135 (-1.91%)

KPRX Kiora Pharmaceuticals
/

+

KDNY Chinook Therapeutics
$14.04 /

-0.29 (-2.02%)

IMAC IMAC
$1.25 /

-0.17 (-11.97%)

IMAB I-Mab
$39.89 /

-0.79 (-1.94%)

HEPA Hepion Pharmaceuticals
$1.23 /

-0.02 (-1.60%)

GRTS Gritstone
$6.88 /

+0.42 (+6.50%)

EQ Equillium
$3.49 /

+0.02 (+0.58%)

EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

EKSO Ekso Bionics
$2.55 /

-0.125 (-4.68%)

DARE Dare Bioscience
$1.74 /

-0.04 (-2.25%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$25.41 /

-0.22 (-0.86%)

CABA Cabaletta Bio
$3.52 /

+0.025 (+0.72%)

BBLG Bone Biologics
$5.27 /

+1.78 (+51.00%)

ANVS Annovis Bio
$16.50 /

-0.445 (-2.63%)

AADI Aadi Bioscience
$22.02 /

+0.065 (+0.30%)

AADI Aadi Bioscience
$22.02 /

+0.065 (+0.30%)

11/24/21 H.C. Wainwright
Aadi Bioscience price target raised to $49 from $47 at H.C. Wainwright
11/23/21 Piper Sandler
Aadi Bioscience price target raised to $50 from $45 at Piper Sandler
11/10/21 Piper Sandler
Piper Sandler bullish on Aadi ahead of expected FDA decision for ABI-009
10/01/21 Cowen
Cowen starts Aadi Bioscience with Outperform, sees upcoming catalysts
ANVS Annovis Bio
$16.50 /

-0.445 (-2.63%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
BBLG Bone Biologics
$5.27 /

+1.78 (+51.00%)

CDXS Codexis
$25.41 /

-0.22 (-0.86%)

12/31/21 Benchmark
Pfizer COVID-19 pill approval in UK could be boost for Codexis, says Benchmark
12/22/21 Craig-Hallum
Craig-Hallum bullish on Codexis, sees potential for upside to 2022 estimates
11/18/21 Benchmark
Pfizer's antiviral pill deal raises Benchmark's confidence in Codexis estimates
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
COCP Cocrystal Pharma
/

+

06/15/21 H.C. Wainwright
Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
DARE Dare Bioscience
$1.74 /

-0.04 (-2.25%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

GRTS Gritstone
$6.88 /

+0.42 (+6.50%)

10/14/21 BTIG
Gritstone assumed with a Buy at BTIG
01/21/21 BTIG
Gritstone Oncology price target raised to $35 from $17 at BTIG
01/20/21 H.C. Wainwright
Gritstone Oncology price target raised to $24 from $16 at H.C. Wainwright
01/20/21 Baird
Gritstone Oncology downgraded to Underperform from Outperform at Baird
IMAC IMAC
$1.25 /

-0.17 (-11.97%)

08/19/21 Alliance Global Partners
IMAC downgraded to Neutral at Alliance Global Partners following Q2 results
08/19/21 Alliance Global Partners
IMAC downgraded to Neutral from Buy at Alliance Global Partners
04/09/21 Alliance Global Partners
IMAC price target lowered to $2.35 from $3.10 at Alliance Global Partners
KPRX Kiora Pharmaceuticals
/

+

LUMO Lumos Pharma
$6.94 /

-0.135 (-1.91%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
OCUL Ocular Therapeutix
$6.49 /

+0.055 (+0.85%)

12/06/21 Piper Sandler
Ocular data warrant advancing acute dry eye program, says Piper Sandler
11/09/21 JMP Securities
Ocular Therapeutix price target raised to $30 from $27 at JMP Securities
10/25/21 H.C. Wainwright
Ocular Therapeutix price target lowered to $14 from $18 at H.C. Wainwright
10/24/21 Piper Sandler
Ocular Therapeutix price target lowered to $20 from $27 at Piper Sandler
PHIO Phio Pharmaceuticals
/

+

06/14/21 H.C. Wainwright
Phio Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
RGLS Regulus
/

+

09/02/21 Cantor Fitzgerald
Regulus initiated with an Overweight at Cantor Fitzgerald
05/14/21 H.C. Wainwright
Regulus price target raised to $2 from $1.50 at H.C. Wainwright
SKYE Skye Bioscience
/

+

TARA Protara Therapeutics
$6.23 /

+0.02 (+0.32%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
TRVN Trevena
/

+

03/15/21 Oppenheimer
Trevena initiated with a Perform at Oppenheimer
VRNA Verona Pharma
$6.83 /

-0.04 (-0.58%)

09/13/21
Fly Intel: Top five analyst initiations
09/13/21 H.C. Wainwright
Verona Pharma initiated with a Buy at H.C. Wainwright
ONCR Oncorus
$4.71 /

+0.16 (+3.52%)

11/12/21 Piper Sandler
Piper would be 'aggressive buyers' of Oncorus after '177 data 'as good as hoped'
06/22/21 Piper Sandler
Oncorus investor day 'incrementally positive,' says Piper Sandler
04/19/21 Piper Sandler
Oncorus selloff has nothing to do with fundamentals, says Piper Sandler
03/16/21
Fly Intel: Top five analyst initiations
HEPA Hepion Pharmaceuticals
$1.23 /

-0.02 (-1.60%)

EQ Equillium
$3.49 /

+0.02 (+0.58%)

10/29/21 Stifel
Equillium resumed with a Buy at Stifel
09/15/21
Fly Intel: Top five analyst initiations
09/15/21 Cantor Fitzgerald
Equillium initiated with an Overweight at Cantor Fitzgerald
03/03/21
Fly Intel: Top five analyst initiations
CLBS Caladrius
/

+

11/05/21 H.C. Wainwright
Caladrius price target lowered to $8 from $10 at H.C. Wainwright
03/03/21 Brookline
Caladrius price target raised to $10 from $7 at Brookline
01/19/21 H.C. Wainwright
Caladrius price target lowered to $14 from $18.50 at H.C. Wainwright
CABA Cabaletta Bio
$3.52 /

+0.025 (+0.72%)

12/08/21 Wells Fargo
Cabaletta Bio initiated with an Overweight at Wells Fargo
10/19/21 Morgan Stanley
Cabaletta Bio assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Cabaletta Bio initiated with a Buy at Mizuho
03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
EKSO Ekso Bionics
$2.55 /

-0.125 (-4.68%)

IMAB I-Mab
$39.89 /

-0.79 (-1.94%)

09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
07/26/21 Cantor Fitzgerald
I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
07/13/21 Cantor Fitzgerald
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
KDNY Chinook Therapeutics
$14.04 /

-0.29 (-2.02%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
MRNS Marinus Pharmaceuticals
$11.35 /

+0.21 (+1.89%)

08/18/21 Truist
Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
03/10/21 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.23 /

+0.02 (+0.32%)

RGLS Regulus
/

+

ONCR Oncorus
$4.71 /

+0.16 (+3.52%)

OCUL Ocular Therapeutix
$6.49 /

+0.055 (+0.85%)

MRNS Marinus Pharmaceuticals
$11.35 /

+0.21 (+1.89%)

LUMO Lumos Pharma
$6.94 /

-0.135 (-1.91%)

KPRX Kiora Pharmaceuticals
/

+

KDNY Chinook Therapeutics
$14.04 /

-0.29 (-2.02%)

IMAC IMAC
$1.25 /

-0.17 (-11.97%)

GRTS Gritstone
$6.88 /

+0.42 (+6.50%)

EQ Equillium
$3.49 /

+0.02 (+0.58%)

EKSO Ekso Bionics
$2.55 /

-0.125 (-4.68%)

DARE Dare Bioscience
$1.74 /

-0.04 (-2.25%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$25.41 /

-0.22 (-0.86%)

CABA Cabaletta Bio
$3.52 /

+0.025 (+0.72%)

AADI Aadi Bioscience
$22.02 /

+0.065 (+0.30%)

  • 10
    Nov
  • 16
    Feb
  • 12
    Feb
  • 09
    Feb
  • 09
    Feb
  • 13
    Jan
TARA Protara Therapeutics
$6.23 /

+0.02 (+0.32%)

RGLS Regulus
/

+

OCUL Ocular Therapeutix
$6.49 /

+0.055 (+0.85%)

LUMO Lumos Pharma
$6.94 /

-0.135 (-1.91%)

GRTS Gritstone
$6.88 /

+0.42 (+6.50%)

EQ Equillium
$3.49 /

+0.02 (+0.58%)

DARE Dare Bioscience
$1.74 /

-0.04 (-2.25%)

CDXS Codexis
$25.41 /

-0.22 (-0.86%)

CABA Cabaletta Bio
$3.52 /

+0.025 (+0.72%)

ANVS Annovis Bio
$16.50 /

-0.445 (-2.63%)

GRTS Gritstone
$6.88 /

+0.42 (+6.50%)

AADI Aadi Bioscience
$22.02 /

+0.065 (+0.30%)

Conference/Events
H.C. Wainwright to hold a virtual conference » 04:55
01/10/22
01/10
04:55
01/10/22
04:55
AADI

Aadi Bioscience

$21.76 /

-0.66 (-2.94%)

, ANVS

Annovis Bio

$16.91 /

-0.355 (-2.06%)

, BBLG

Bone Biologics

$3.52 /

-0.1 (-2.76%)

, CDXS

Codexis

$25.58 /

-1.09 (-4.09%)

, COCP

Cocrystal Pharma

/

+

, DARE

Dare Bioscience

$1.78 /

-0.06 (-3.27%)

, EMMA

Emmaus Life Sciences

$2.78 /

+ (+0.00%)

, GRTS

Gritstone

$6.46 /

-0.265 (-3.94%)

, IMAC

IMAC

$1.42 /

+0.03 (+2.16%)

, KPRX

Kiora Pharmaceuticals

$1.01 /

-0.035 (-3.37%)

, LUMO

Lumos Pharma

$7.07 /

-0.03 (-0.42%)

, OCUL

Ocular Therapeutix

$6.44 /

-0.14 (-2.13%)

, PHIO

Phio Pharmaceuticals

/

+

, RGLS

Regulus

/

+

, SKYE

Skye Bioscience

/

+

, TARA

Protara Therapeutics

$6.21 /

+0.04 (+0.65%)

, TRVN

Trevena

/

+

, VRNA

Verona Pharma

$6.92 /

-0.13 (-1.84%)

, ONCR

Oncorus

$4.54 /

-0.23 (-4.82%)

, HEPA

Hepion Pharmaceuticals

$1.25 /

+0.035 (+2.88%)

, EQ

Equillium

$3.47 /

+0.02 (+0.58%)

, CLBS

Caladrius

/

+

, CABA

Cabaletta Bio

$3.49 /

-0.36 (-9.35%)

, EKSO

Ekso Bionics

$2.67 /

+0.045 (+1.71%)

, IMAB

I-Mab

$40.69 /

+0.79 (+1.98%)

, KDNY

Chinook Therapeutics

$14.34 /

-0.98 (-6.40%)

, MRNS

Marinus Pharmaceuticals

$11.10 /

-0.26 (-2.29%)

Bioconnect Virtual…

Bioconnect Virtual Conference to be held on January 10-13.

ShowHide Related Items >><<
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.21 /

+0.04 (+0.65%)

SKYE Skye Bioscience
/

+

RGLS Regulus
/

+

PHIO Phio Pharmaceuticals
/

+

ONCR Oncorus
$4.54 /

-0.23 (-4.82%)

OCUL Ocular Therapeutix
$6.44 /

-0.14 (-2.13%)

MRNS Marinus Pharmaceuticals
$11.10 /

-0.26 (-2.29%)

LUMO Lumos Pharma
$7.07 /

-0.03 (-0.42%)

KPRX Kiora Pharmaceuticals
$1.01 /

-0.035 (-3.37%)

KDNY Chinook Therapeutics
$14.34 /

-0.98 (-6.40%)

IMAC IMAC
$1.42 /

+0.03 (+2.16%)

IMAB I-Mab
$40.69 /

+0.79 (+1.98%)

HEPA Hepion Pharmaceuticals
$1.25 /

+0.035 (+2.88%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

EQ Equillium
$3.47 /

+0.02 (+0.58%)

EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

EKSO Ekso Bionics
$2.67 /

+0.045 (+1.71%)

DARE Dare Bioscience
$1.78 /

-0.06 (-3.27%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$25.58 /

-1.09 (-4.09%)

CABA Cabaletta Bio
$3.49 /

-0.36 (-9.35%)

BBLG Bone Biologics
$3.52 /

-0.1 (-2.76%)

ANVS Annovis Bio
$16.91 /

-0.355 (-2.06%)

AADI Aadi Bioscience
$21.76 /

-0.66 (-2.94%)

AADI Aadi Bioscience
$21.76 /

-0.66 (-2.94%)

11/24/21 H.C. Wainwright
Aadi Bioscience price target raised to $49 from $47 at H.C. Wainwright
11/23/21 Piper Sandler
Aadi Bioscience price target raised to $50 from $45 at Piper Sandler
11/10/21 Piper Sandler
Piper Sandler bullish on Aadi ahead of expected FDA decision for ABI-009
10/01/21 Cowen
Cowen starts Aadi Bioscience with Outperform, sees upcoming catalysts
ANVS Annovis Bio
$16.91 /

-0.355 (-2.06%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
BBLG Bone Biologics
$3.52 /

-0.1 (-2.76%)

CDXS Codexis
$25.58 /

-1.09 (-4.09%)

12/31/21 Benchmark
Pfizer COVID-19 pill approval in UK could be boost for Codexis, says Benchmark
12/22/21 Craig-Hallum
Craig-Hallum bullish on Codexis, sees potential for upside to 2022 estimates
11/18/21 Benchmark
Pfizer's antiviral pill deal raises Benchmark's confidence in Codexis estimates
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
COCP Cocrystal Pharma
/

+

06/15/21 H.C. Wainwright
Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
DARE Dare Bioscience
$1.78 /

-0.06 (-3.27%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

10/14/21 BTIG
Gritstone assumed with a Buy at BTIG
01/21/21 BTIG
Gritstone Oncology price target raised to $35 from $17 at BTIG
01/20/21 H.C. Wainwright
Gritstone Oncology price target raised to $24 from $16 at H.C. Wainwright
01/20/21 Baird
Gritstone Oncology downgraded to Underperform from Outperform at Baird
IMAC IMAC
$1.42 /

+0.03 (+2.16%)

08/19/21 Alliance Global Partners
IMAC downgraded to Neutral at Alliance Global Partners following Q2 results
08/19/21 Alliance Global Partners
IMAC downgraded to Neutral from Buy at Alliance Global Partners
04/09/21 Alliance Global Partners
IMAC price target lowered to $2.35 from $3.10 at Alliance Global Partners
KPRX Kiora Pharmaceuticals
$1.01 /

-0.035 (-3.37%)

LUMO Lumos Pharma
$7.07 /

-0.03 (-0.42%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
OCUL Ocular Therapeutix
$6.44 /

-0.14 (-2.13%)

12/06/21 Piper Sandler
Ocular data warrant advancing acute dry eye program, says Piper Sandler
11/09/21 JMP Securities
Ocular Therapeutix price target raised to $30 from $27 at JMP Securities
10/25/21 H.C. Wainwright
Ocular Therapeutix price target lowered to $14 from $18 at H.C. Wainwright
10/24/21 Piper Sandler
Ocular Therapeutix price target lowered to $20 from $27 at Piper Sandler
PHIO Phio Pharmaceuticals
/

+

06/14/21 H.C. Wainwright
Phio Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
RGLS Regulus
/

+

09/02/21 Cantor Fitzgerald
Regulus initiated with an Overweight at Cantor Fitzgerald
05/14/21 H.C. Wainwright
Regulus price target raised to $2 from $1.50 at H.C. Wainwright
SKYE Skye Bioscience
/

+

TARA Protara Therapeutics
$6.21 /

+0.04 (+0.65%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
TRVN Trevena
/

+

03/15/21 Oppenheimer
Trevena initiated with a Perform at Oppenheimer
VRNA Verona Pharma
$6.92 /

-0.13 (-1.84%)

09/13/21
Fly Intel: Top five analyst initiations
09/13/21 H.C. Wainwright
Verona Pharma initiated with a Buy at H.C. Wainwright
ONCR Oncorus
$4.54 /

-0.23 (-4.82%)

11/12/21 Piper Sandler
Piper would be 'aggressive buyers' of Oncorus after '177 data 'as good as hoped'
06/22/21 Piper Sandler
Oncorus investor day 'incrementally positive,' says Piper Sandler
04/19/21 Piper Sandler
Oncorus selloff has nothing to do with fundamentals, says Piper Sandler
03/16/21
Fly Intel: Top five analyst initiations
HEPA Hepion Pharmaceuticals
$1.25 /

+0.035 (+2.88%)

EQ Equillium
$3.47 /

+0.02 (+0.58%)

10/29/21 Stifel
Equillium resumed with a Buy at Stifel
09/15/21
Fly Intel: Top five analyst initiations
09/15/21 Cantor Fitzgerald
Equillium initiated with an Overweight at Cantor Fitzgerald
03/03/21
Fly Intel: Top five analyst initiations
CLBS Caladrius
/

+

11/05/21 H.C. Wainwright
Caladrius price target lowered to $8 from $10 at H.C. Wainwright
03/03/21 Brookline
Caladrius price target raised to $10 from $7 at Brookline
01/19/21 H.C. Wainwright
Caladrius price target lowered to $14 from $18.50 at H.C. Wainwright
CABA Cabaletta Bio
$3.49 /

-0.36 (-9.35%)

12/08/21 Wells Fargo
Cabaletta Bio initiated with an Overweight at Wells Fargo
10/19/21 Morgan Stanley
Cabaletta Bio assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Cabaletta Bio initiated with a Buy at Mizuho
03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
EKSO Ekso Bionics
$2.67 /

+0.045 (+1.71%)

IMAB I-Mab
$40.69 /

+0.79 (+1.98%)

09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
07/26/21 Cantor Fitzgerald
I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
07/13/21 Cantor Fitzgerald
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
KDNY Chinook Therapeutics
$14.34 /

-0.98 (-6.40%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
MRNS Marinus Pharmaceuticals
$11.10 /

-0.26 (-2.29%)

08/18/21 Truist
Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
03/10/21 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.21 /

+0.04 (+0.65%)

RGLS Regulus
/

+

ONCR Oncorus
$4.54 /

-0.23 (-4.82%)

OCUL Ocular Therapeutix
$6.44 /

-0.14 (-2.13%)

MRNS Marinus Pharmaceuticals
$11.10 /

-0.26 (-2.29%)

LUMO Lumos Pharma
$7.07 /

-0.03 (-0.42%)

KPRX Kiora Pharmaceuticals
$1.01 /

-0.035 (-3.37%)

KDNY Chinook Therapeutics
$14.34 /

-0.98 (-6.40%)

IMAC IMAC
$1.42 /

+0.03 (+2.16%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

EQ Equillium
$3.47 /

+0.02 (+0.58%)

EKSO Ekso Bionics
$2.67 /

+0.045 (+1.71%)

DARE Dare Bioscience
$1.78 /

-0.06 (-3.27%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$25.58 /

-1.09 (-4.09%)

CABA Cabaletta Bio
$3.49 /

-0.36 (-9.35%)

AADI Aadi Bioscience
$21.76 /

-0.66 (-2.94%)

  • 10
    Nov
  • 16
    Feb
  • 12
    Feb
  • 09
    Feb
  • 09
    Feb
  • 13
    Jan
TARA Protara Therapeutics
$6.21 /

+0.04 (+0.65%)

RGLS Regulus
/

+

OCUL Ocular Therapeutix
$6.44 /

-0.14 (-2.13%)

LUMO Lumos Pharma
$7.07 /

-0.03 (-0.42%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

EQ Equillium
$3.47 /

+0.02 (+0.58%)

DARE Dare Bioscience
$1.78 /

-0.06 (-3.27%)

CDXS Codexis
$25.58 /

-1.09 (-4.09%)

CABA Cabaletta Bio
$3.49 /

-0.36 (-9.35%)

ANVS Annovis Bio
$16.91 /

-0.355 (-2.06%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

AADI Aadi Bioscience
$21.76 /

-0.66 (-2.94%)

Conference/Events
H.C. Wainwright to hold a virtual conference » 17:30
01/09/22
01/09
17:30
01/09/22
17:30
AADI

Aadi Bioscience

$21.76 /

-0.66 (-2.94%)

, ANVS

Annovis Bio

$16.91 /

-0.355 (-2.06%)

, BBLG

Bone Biologics

$3.52 /

-0.1 (-2.76%)

, CDXS

Codexis

$25.58 /

-1.09 (-4.09%)

, COCP

Cocrystal Pharma

/

+

, DARE

Dare Bioscience

$1.78 /

-0.06 (-3.27%)

, EMMA

Emmaus Life Sciences

$2.78 /

+ (+0.00%)

, GRTS

Gritstone

$6.46 /

-0.265 (-3.94%)

, IMAC

IMAC

$1.42 /

+0.03 (+2.16%)

, KPRX

Kiora Pharmaceuticals

$1.01 /

-0.035 (-3.37%)

, LUMO

Lumos Pharma

$7.07 /

-0.03 (-0.42%)

, OCUL

Ocular Therapeutix

$6.44 /

-0.14 (-2.13%)

, PHIO

Phio Pharmaceuticals

/

+

, RGLS

Regulus

/

+

, SKYE

Skye Bioscience

/

+

, TARA

Protara Therapeutics

$6.21 /

+0.04 (+0.65%)

, TRVN

Trevena

/

+

, VRNA

Verona Pharma

$6.92 /

-0.13 (-1.84%)

, ONCR

Oncorus

$4.54 /

-0.23 (-4.82%)

, HEPA

Hepion Pharmaceuticals

$1.25 /

+0.035 (+2.88%)

, EQ

Equillium

$3.47 /

+0.02 (+0.58%)

, CLBS

Caladrius

/

+

, CABA

Cabaletta Bio

$3.49 /

-0.36 (-9.35%)

, EKSO

Ekso Bionics

$2.67 /

+0.045 (+1.71%)

, IMAB

I-Mab

$40.69 /

+0.79 (+1.98%)

, KDNY

Chinook Therapeutics

$14.34 /

-0.98 (-6.40%)

, MRNS

Marinus Pharmaceuticals

$11.10 /

-0.26 (-2.29%)

Bioconnect Virtual…

Bioconnect Virtual Conference to be held on January 10-13.

ShowHide Related Items >><<
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.21 /

+0.04 (+0.65%)

SKYE Skye Bioscience
/

+

RGLS Regulus
/

+

PHIO Phio Pharmaceuticals
/

+

ONCR Oncorus
$4.54 /

-0.23 (-4.82%)

OCUL Ocular Therapeutix
$6.44 /

-0.14 (-2.13%)

MRNS Marinus Pharmaceuticals
$11.10 /

-0.26 (-2.29%)

LUMO Lumos Pharma
$7.07 /

-0.03 (-0.42%)

KPRX Kiora Pharmaceuticals
$1.01 /

-0.035 (-3.37%)

KDNY Chinook Therapeutics
$14.34 /

-0.98 (-6.40%)

IMAC IMAC
$1.42 /

+0.03 (+2.16%)

IMAB I-Mab
$40.69 /

+0.79 (+1.98%)

HEPA Hepion Pharmaceuticals
$1.25 /

+0.035 (+2.88%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

EQ Equillium
$3.47 /

+0.02 (+0.58%)

EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

EKSO Ekso Bionics
$2.67 /

+0.045 (+1.71%)

DARE Dare Bioscience
$1.78 /

-0.06 (-3.27%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$25.58 /

-1.09 (-4.09%)

CABA Cabaletta Bio
$3.49 /

-0.36 (-9.35%)

BBLG Bone Biologics
$3.52 /

-0.1 (-2.76%)

ANVS Annovis Bio
$16.91 /

-0.355 (-2.06%)

AADI Aadi Bioscience
$21.76 /

-0.66 (-2.94%)

AADI Aadi Bioscience
$21.76 /

-0.66 (-2.94%)

11/24/21 H.C. Wainwright
Aadi Bioscience price target raised to $49 from $47 at H.C. Wainwright
11/23/21 Piper Sandler
Aadi Bioscience price target raised to $50 from $45 at Piper Sandler
11/10/21 Piper Sandler
Piper Sandler bullish on Aadi ahead of expected FDA decision for ABI-009
10/01/21 Cowen
Cowen starts Aadi Bioscience with Outperform, sees upcoming catalysts
ANVS Annovis Bio
$16.91 /

-0.355 (-2.06%)

05/13/21 Maxim
Annovis Bio price target raised to $45 from $12 at Maxim
BBLG Bone Biologics
$3.52 /

-0.1 (-2.76%)

CDXS Codexis
$25.58 /

-1.09 (-4.09%)

12/31/21 Benchmark
Pfizer COVID-19 pill approval in UK could be boost for Codexis, says Benchmark
12/22/21 Craig-Hallum
Craig-Hallum bullish on Codexis, sees potential for upside to 2022 estimates
11/18/21 Benchmark
Pfizer's antiviral pill deal raises Benchmark's confidence in Codexis estimates
11/05/21 Benchmark
Codexis price target raised to $45 from $29 at Benchmark
COCP Cocrystal Pharma
/

+

06/15/21 H.C. Wainwright
Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
DARE Dare Bioscience
$1.78 /

-0.06 (-3.27%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
EMMA Emmaus Life Sciences
$2.78 /

+ (+0.00%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

10/14/21 BTIG
Gritstone assumed with a Buy at BTIG
01/21/21 BTIG
Gritstone Oncology price target raised to $35 from $17 at BTIG
01/20/21 H.C. Wainwright
Gritstone Oncology price target raised to $24 from $16 at H.C. Wainwright
01/20/21 Baird
Gritstone Oncology downgraded to Underperform from Outperform at Baird
IMAC IMAC
$1.42 /

+0.03 (+2.16%)

08/19/21 Alliance Global Partners
IMAC downgraded to Neutral at Alliance Global Partners following Q2 results
08/19/21 Alliance Global Partners
IMAC downgraded to Neutral from Buy at Alliance Global Partners
04/09/21 Alliance Global Partners
IMAC price target lowered to $2.35 from $3.10 at Alliance Global Partners
KPRX Kiora Pharmaceuticals
$1.01 /

-0.035 (-3.37%)

LUMO Lumos Pharma
$7.07 /

-0.03 (-0.42%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
OCUL Ocular Therapeutix
$6.44 /

-0.14 (-2.13%)

12/06/21 Piper Sandler
Ocular data warrant advancing acute dry eye program, says Piper Sandler
11/09/21 JMP Securities
Ocular Therapeutix price target raised to $30 from $27 at JMP Securities
10/25/21 H.C. Wainwright
Ocular Therapeutix price target lowered to $14 from $18 at H.C. Wainwright
10/24/21 Piper Sandler
Ocular Therapeutix price target lowered to $20 from $27 at Piper Sandler
PHIO Phio Pharmaceuticals
/

+

06/14/21 H.C. Wainwright
Phio Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
RGLS Regulus
/

+

09/02/21 Cantor Fitzgerald
Regulus initiated with an Overweight at Cantor Fitzgerald
05/14/21 H.C. Wainwright
Regulus price target raised to $2 from $1.50 at H.C. Wainwright
SKYE Skye Bioscience
/

+

TARA Protara Therapeutics
$6.21 /

+0.04 (+0.65%)

06/04/21 H.C. Wainwright
Protara Therapeutics initiated with a Buy at H.C. Wainwright
04/26/21 Oppenheimer
Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
TRVN Trevena
/

+

03/15/21 Oppenheimer
Trevena initiated with a Perform at Oppenheimer
VRNA Verona Pharma
$6.92 /

-0.13 (-1.84%)

09/13/21
Fly Intel: Top five analyst initiations
09/13/21 H.C. Wainwright
Verona Pharma initiated with a Buy at H.C. Wainwright
ONCR Oncorus
$4.54 /

-0.23 (-4.82%)

11/12/21 Piper Sandler
Piper would be 'aggressive buyers' of Oncorus after '177 data 'as good as hoped'
06/22/21 Piper Sandler
Oncorus investor day 'incrementally positive,' says Piper Sandler
04/19/21 Piper Sandler
Oncorus selloff has nothing to do with fundamentals, says Piper Sandler
03/16/21
Fly Intel: Top five analyst initiations
HEPA Hepion Pharmaceuticals
$1.25 /

+0.035 (+2.88%)

EQ Equillium
$3.47 /

+0.02 (+0.58%)

10/29/21 Stifel
Equillium resumed with a Buy at Stifel
09/15/21
Fly Intel: Top five analyst initiations
09/15/21 Cantor Fitzgerald
Equillium initiated with an Overweight at Cantor Fitzgerald
03/03/21
Fly Intel: Top five analyst initiations
CLBS Caladrius
/

+

11/05/21 H.C. Wainwright
Caladrius price target lowered to $8 from $10 at H.C. Wainwright
03/03/21 Brookline
Caladrius price target raised to $10 from $7 at Brookline
01/19/21 H.C. Wainwright
Caladrius price target lowered to $14 from $18.50 at H.C. Wainwright
CABA Cabaletta Bio
$3.49 /

-0.36 (-9.35%)

12/08/21 Wells Fargo
Cabaletta Bio initiated with an Overweight at Wells Fargo
10/19/21 Morgan Stanley
Cabaletta Bio assumed with an Overweight at Morgan Stanley
06/29/21 Mizuho
Cabaletta Bio initiated with a Buy at Mizuho
03/17/21 H.C. Wainwright
Cabaletta Bio price target raised to $22 from $20 at H.C. Wainwright
EKSO Ekso Bionics
$2.67 /

+0.045 (+1.71%)

IMAB I-Mab
$40.69 /

+0.79 (+1.98%)

09/03/21 Cantor Fitzgerald
Cantor Fitzgerald positive on I-Mab following 'solid' first half
09/01/21 H.C. Wainwright
I-Mab price target raised to $95 from $75 at H.C. Wainwright
07/26/21 Cantor Fitzgerald
I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
07/13/21 Cantor Fitzgerald
I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
KDNY Chinook Therapeutics
$14.34 /

-0.98 (-6.40%)

04/05/21 H.C. Wainwright
Chinook spinoff 'prudent way' to maximize Aduro value, says H.C. Wainwright
03/30/21 Cantor Fitzgerald
Cantor says Chinook BION-1301 abstract suggests positive proof of concept
MRNS Marinus Pharmaceuticals
$11.10 /

-0.26 (-2.29%)

08/18/21 Truist
Marinus Pharmaceuticals price target raised to $40 from $35 at Truist
03/10/21 H.C. Wainwright
Marinus Pharmaceuticals price target raised to $38 from $35 at H.C. Wainwright
TRVN Trevena
/

+

TARA Protara Therapeutics
$6.21 /

+0.04 (+0.65%)

RGLS Regulus
/

+

ONCR Oncorus
$4.54 /

-0.23 (-4.82%)

OCUL Ocular Therapeutix
$6.44 /

-0.14 (-2.13%)

MRNS Marinus Pharmaceuticals
$11.10 /

-0.26 (-2.29%)

LUMO Lumos Pharma
$7.07 /

-0.03 (-0.42%)

KPRX Kiora Pharmaceuticals
$1.01 /

-0.035 (-3.37%)

KDNY Chinook Therapeutics
$14.34 /

-0.98 (-6.40%)

IMAC IMAC
$1.42 /

+0.03 (+2.16%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

EQ Equillium
$3.47 /

+0.02 (+0.58%)

EKSO Ekso Bionics
$2.67 /

+0.045 (+1.71%)

DARE Dare Bioscience
$1.78 /

-0.06 (-3.27%)

COCP Cocrystal Pharma
/

+

CLBS Caladrius
/

+

CDXS Codexis
$25.58 /

-1.09 (-4.09%)

CABA Cabaletta Bio
$3.49 /

-0.36 (-9.35%)

AADI Aadi Bioscience
$21.76 /

-0.66 (-2.94%)

  • 10
    Nov
  • 16
    Feb
  • 12
    Feb
  • 09
    Feb
  • 09
    Feb
  • 13
    Jan
TARA Protara Therapeutics
$6.21 /

+0.04 (+0.65%)

RGLS Regulus
/

+

OCUL Ocular Therapeutix
$6.44 /

-0.14 (-2.13%)

LUMO Lumos Pharma
$7.07 /

-0.03 (-0.42%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

EQ Equillium
$3.47 /

+0.02 (+0.58%)

DARE Dare Bioscience
$1.78 /

-0.06 (-3.27%)

CDXS Codexis
$25.58 /

-1.09 (-4.09%)

CABA Cabaletta Bio
$3.49 /

-0.36 (-9.35%)

ANVS Annovis Bio
$16.91 /

-0.355 (-2.06%)

GRTS Gritstone
$6.46 /

-0.265 (-3.94%)

AADI Aadi Bioscience
$21.76 /

-0.66 (-2.94%)

Over a month ago
Hot Stocks
Dare Bioscience Inc trading resumes  16:45
12/07/21
12/07
16:45
12/07/21
16:45
DARE

Dare Bioscience

$2.13 /

+0.21 (+10.94%)

 
ShowHide Related Items >><<
DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

Hot Stocks
Dare announces FDA approval of XACIATO vaginal gel for bacterial vaginosis » 16:21
12/07/21
12/07
16:21
12/07/21
16:21
DARE

Dare Bioscience

$2.13 /

+0.21 (+10.94%)

Dare Bioscience announced…

Dare Bioscience announced that the U.S. Food and Drug Administration approved XACIATO for the treatment of bacterial vaginosis in females 12 years of age and older. "The FDA approval of XACIATO marks a major milestone not only for Dare as a company but, importantly, for the 21 million women impacted by bacterial vaginosis," said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. "It is our goal as a company to accelerate the development of differentiated products that can improve outcomes and convenience for women. In the case of XACIATO, this FDA approval comes just three years after we licensed this technology. We are grateful to the FDA for their thoughtful review and the alignment on labeling that gives healthcare providers clear insights into how to use XACIATO in those patient populations in greatest need of a therapeutic option, such as pregnant women and women with recurrent episodes of bacterial vaginosis. We hope that this is the first of many FDA approvals in our efforts to improve the lives of women with treatment options that address some of the most persistent unmet needs." "Bacterial vaginosis is not a sexually transmitted infection, but rather an overgrowth of bacteria naturally found in the vagina, which upsets the balance of the natural vaginal microbiome and leads to not only distressing symptoms of odor and discharge, but also increases a woman's risk of preterm birth, infertility, and infections. Today, approximately half of the women treated for bacterial vaginosis experience a recurrence within 12 months of treatment. There is a need for more efficacious and convenient treatment options, particularly products with improved clinical outcomes for not only the newly diagnosed women, but, importantly, also for the women who experience multiple episodes of bacterial vaginosis each year," said David Friend, Ph.D., Dare's Chief Scientific Officer. "Now that we have achieved this important demonstration of this drug delivery hydrogel platform technology, we are actively exploring the opportunity to leverage it across other unmet needs in women's health."

ShowHide Related Items >><<
DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

Hot Stocks
FDA approves Dare Bioscience's Xaciato vaginal gel » 12:33
12/07/21
12/07
12:33
12/07/21
12:33
DARE

Dare Bioscience

$2.13 /

+0.21 (+10.94%)

A post to the site of the…

A post to the site of the FDA indicates that Dare Bioscience's Xaciato vaginal gel was granted approval for the indication of treatment of bacterial vaginosis in female patients 12 years of age and older. Shares Dare Bioscience were halted, pending news, ahead of the decision from the FDA on DARE-BV1, which was assigned a PDUFA date of December 7. Dare shares remain halted for trading as of the time of this writing. Reference Link

ShowHide Related Items >><<
DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

DARE Dare Bioscience
$2.13 /

+0.21 (+10.94%)

Hot Stocks
Dare Bioscience Inc trading halted, news pending  11:16
12/07/21
12/07
11:16
12/07/21
11:16
DARE

Dare Bioscience

$2.12 /

+0.2 (+10.42%)

 
ShowHide Related Items >><<
DARE Dare Bioscience
$2.12 /

+0.2 (+10.42%)

DARE Dare Bioscience
$2.12 /

+0.2 (+10.42%)

07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
06/30/21 Roth Capital
Roth Capital ups Dare target to $11, says PK data for DARE-HRT1 validates tech
DARE Dare Bioscience
$2.12 /

+0.2 (+10.42%)

DARE Dare Bioscience
$2.12 /

+0.2 (+10.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.